Amgen Aktie
250,85 EUR +0,30 EUR +0,12 %
STU
258,58 USD -2,61 USD -1,00 %
nachbörslichBTT
BTT
Werbung
Amgen Rating
Amgen Inc. Aktie Moody's Rating
Baa1
C
A3
Aaa
Investmentwürdig - Hohe Sicherheit
Investmentwürdig - Mittlere Sicherheit
Nicht als Investment geeignet
Investmentwürdig - Mittlere Sicherheit
Nicht als Investment geeignet
| Rating | Baa1 | Rating Typ Bank Financial Strength Rating Insurance Financial Strength Rating Enhanced Rating Insured Rating Long-Term Bank Deposit Rating Long-Term OSO Rating Long-Term Debt Rating Money Market Fund Rating Modeled Shadow Rating Management Quality Rating Probability of Default Rating Pfd/Pref Stock Rating Prospective Pfd/Pref Rating Short-Term Bank Deposit Rating Speculative Grade Liquidity Rating Prospective LT Debt Rating Short-Term Insurance Financial Strength Rating Short-Term OSO Rating Servicer Quality Short-Term Debt Rating Lloyd´s Syndicate Performance Rating Underlying Rating Unknown - for conversion use only | Long-Term Debt Rating |
| Letzte Aktion | AFFIRM | Moody's Büro in | - |
Anleihen von Amgen Inc. mit Moody's Ratings
| Emittent | Anzahl Anleihen | Ratings |
|---|---|---|
| Amgen Inc. | 40 | Baa1 |
Moody's Ratings Peer Group
| Aktie | Rating |
|---|---|
| Bayer | Baa3 |
| Biogen Inc | Baa2 |
| Gilead Sciences Inc. | A3 |
| Sanofi S.A. | A1 |
Beste Ratings aus der gleichen Branche
| Aktie | Rating |
|---|---|
| Pfizer Inc. | A1 |
| General Electric Co. | A1 |
| Sanofi S.A. | A1 |
| Gilead Sciences Inc. | A3 |
| Celgene Corp. | A3 |
| Merck KGaA | A3 |
| Johnson & Johnson | Aaa |
| Regeneron Pharmaceuticals Inc. | Baa1 |
| Biogen Inc | Baa2 |
| Bayer | Baa3 |